Prognostic Value of Alternative Lengthening of Telomeres-Associated Biomarkers in Uterine Sarcoma and Uterine Carcinosarcoma

• DOI: 10.1097/igc.0b013e31823ca017
• Publication Date: 2012-01-20T10:10:36Z
• Authors: Yoo-Kyung Lee; Noh-Hyun Park; Hyunsook Lee
• Keywords: Carcinosarcoma; Uterine sarcoma; Uterine cancer

A subset of cancer cells maintains telomere lengths in a telomerase-independent manner known as the alternative lengthening telomeres (ALT). The goal this study was to evaluate frequency ALT uterine sarcoma and carcinosarcoma assess its association with clinical parameters.Retrospectively collected paraffin blocks from 41 patients sarcomas carcinosarcomas were analyzed for ALT-associated promyelocytic leukemia bodies (APBs), which are significant feature cells, using combined immunofluorescence fluorescence situ hybridization. In addition, C-circle assay human telomerase reverse transcriptase immunohistochemistry performed support these results.The APB indicated that 46.3% (19/41 cases) 36.4% (8/22 uterus, respectively, positive ALT. Alternative positivity correlated high-grade parameters indicative an aggressive tumor, such tumor size (P = 0.033) mitotic index 0.001); negatively reactivity 0.036). survival analysis, presence APBs found be poor prognostic factor disease-free 0.018) overall 0.021).Alternative is prevalent mechanism associated aggressiveness progression. Importantly, indicator prognosis carcinosarcoma.